Dermatology experts highlight advancements in personalized care and new drug developments

Recent developments in dermatology highlight a shift toward personalized, long-term skincare and significant pharmacological breakthroughs. Experts note that skincare should evolve alongside a patient's needs; for instance, once acne is controlled, treatment can transition from active clearing to prevention and skin longevity by adjusting ingredient concentrations.

In clinical advancements, 2026 has seen the rise of oral psoriasis drugs that rival the efficacy of biologics. The FDA approval of icotyde, a once-daily targeted peptide, marks a milestone as the first oral interleukin-23 receptor antagonist. Other notable progress includes the expansion of treatments like Sotyktu for psoriatic arthritis, the approval of Skyrizi for children, and the development of personalized mRNA vaccines for melanoma.